ENSC logo

ENSYSCE BIOSCIENCES INC

ENSCNASDAQ
๐Ÿ† #4875 by market capUS Equity
$0.36โ–ผ $0.02 (โˆ’5.85%)
Market closed ยท at close
๐Ÿ””
Track ENSC
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 5.8%
7dโ–ผ 14.1%
14dโ–ฒ 10.7%
30dโ–ผ 30.8%
ytdโ–ผ 61.5%
1yโ–ผ 77.8%
๐ŸฆMarket Cap
$7M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-39.3%
Declining
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
1.6x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.36 โ€“ $0.36
52-Week Range
$0.23 โ€“ $2.04
Volume (shares)
200
Avg Volume (shares)
โ€”
Shares Outstanding
19.5M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
1.6x
EPS (TTM)
$-2.75
Dividend Yield
โ€”
ENSC logo

ENSYSCE BIOSCIENCES INC

ENSC
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ENSYSCE BIOSCIENCES INC

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.